|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
B-raf V600E protein analysis revealed a subjacent layer of heterogeneity for mutation-positive metastatic melanomas.
|
31835364 |
2019 |
|
rs121913377
|
|
|
0.800 |
GeneticVariation |
BEFREE |
B-raf V600E protein analysis revealed a subjacent layer of heterogeneity for mutation-positive metastatic melanomas.
|
31835364 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Chronic sun-damaged (CSD) melanoma represents 10%-20% of cutaneous melanomas and is characterized by infrequent BRAF V600E mutations and high mutational load.
|
31811783 |
2019 |
|
rs121913377
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Chronic sun-damaged (CSD) melanoma represents 10%-20% of cutaneous melanomas and is characterized by infrequent BRAF V600E mutations and high mutational load.
|
31811783 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAF V600E/K mutant melanoma.
|
31796433 |
2020 |
|
rs121913377
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAF V600E/K mutant melanoma.
|
31796433 |
2020 |
|
rs10816595
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Individuals having melanoma in a visibly UV-damaged site were more likely to carry MC1R rs75570604 (odds ratio [OR] 2.5), 9q31.2 rs10816595 (OR 2.5), and MTAP rs869329 (OR 1.4); these same alleles were more common in MPM patients diagnosed ≤40 years.
|
31794051 |
2019 |
|
rs75570604
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Individuals having melanoma in a visibly UV-damaged site were more likely to carry MC1R rs75570604 (odds ratio [OR] 2.5), 9q31.2 rs10816595 (OR 2.5), and MTAP rs869329 (OR 1.4); these same alleles were more common in MPM patients diagnosed ≤40 years.
|
31794051 |
2019 |
|
rs869329
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Individuals having melanoma in a visibly UV-damaged site were more likely to carry MC1R rs75570604 (odds ratio [OR] 2.5), 9q31.2 rs10816595 (OR 2.5), and MTAP rs869329 (OR 1.4); these same alleles were more common in MPM patients diagnosed ≤40 years.
|
31794051 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
While under normoxic conditions the expression of glycolysis-related genes showed no correlation with origin or BRAF mutation status, GLUT1 expression was significantly elevated in metastatic and BRAF-V600E mutated melanoma cell lines under hypoxic conditions.
|
31791701 |
2020 |
|
rs121913377
|
|
|
0.800 |
GeneticVariation |
BEFREE |
While under normoxic conditions the expression of glycolysis-related genes showed no correlation with origin or BRAF mutation status, GLUT1 expression was significantly elevated in metastatic and BRAF-V600E mutated melanoma cell lines under hypoxic conditions.
|
31791701 |
2020 |
|
rs763538721
|
|
|
0.040 |
GeneticVariation |
BEFREE |
While under normoxic conditions the expression of glycolysis-related genes showed no correlation with origin or BRAF mutation status, GLUT1 expression was significantly elevated in metastatic and BRAF-V600E mutated melanoma cell lines under hypoxic conditions.
|
31791701 |
2020 |
|
rs2234663
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The present study investigated whether a variable number tandem repeat (VNTR) polymorphism of interleukin-1 receptor antagonist (IL-1RA) gene (<i>IL-1RN</i>) located in intron 2 (rs2234663) is associated with cutaneous melanoma.
|
31788049 |
2019 |
|
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Management of V600E and V600K BRAF-Mutant Melanoma.
|
31741065 |
2019 |
|
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The kinetics of ctDNA derived from each cancer type were monitored targeting BRAF V600R (melanoma) and KRAS G13D (colon cancer), specifically reflected the status of the patient's tumours.
|
31727009 |
2019 |
|
rs112445441
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The kinetics of ctDNA derived from each cancer type were monitored targeting BRAF V600R (melanoma) and KRAS G13D (colon cancer), specifically reflected the status of the patient's tumours.
|
31727009 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Importantly, ERK1/2 inhibition may have clinical utility in overcoming acquired resistance to RAF and MEK inhibitors, where RAS/MAPK pathway reactivation has occurred, such as relapsed BRAF V600E/K melanoma.
|
31710489 |
2019 |
|
rs121913377
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Importantly, ERK1/2 inhibition may have clinical utility in overcoming acquired resistance to RAF and MEK inhibitors, where RAS/MAPK pathway reactivation has occurred, such as relapsed BRAF V600E/K melanoma.
|
31710489 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
CTC profiling was performed using 5 known melanoma mRNA biomarkers and BRAF V600E DNA mutation.
|
31672856 |
2019 |
|
rs121913377
|
|
|
0.800 |
GeneticVariation |
BEFREE |
CTC profiling was performed using 5 known melanoma mRNA biomarkers and BRAF V600E DNA mutation.
|
31672856 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Orthogonal partial least squares (O-PLS) predicted vemurafenib sensitivity with greater accuracy in both melanoma and non-melanoma BRAF-V600E cell lines than other leading machine learning methods, specifically Random Forests, Support Vector Regression (linear and quadratic kernels) and LASSO-penalized regression.
|
31672130 |
2019 |
|
rs121913377
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Orthogonal partial least squares (O-PLS) predicted vemurafenib sensitivity with greater accuracy in both melanoma and non-melanoma BRAF-V600E cell lines than other leading machine learning methods, specifically Random Forests, Support Vector Regression (linear and quadratic kernels) and LASSO-penalized regression.
|
31672130 |
2019 |
|
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Orthogonal partial least squares (O-PLS) predicted vemurafenib sensitivity with greater accuracy in both melanoma and non-melanoma BRAF-V600E cell lines than other leading machine learning methods, specifically Random Forests, Support Vector Regression (linear and quadratic kernels) and LASSO-penalized regression.
|
31672130 |
2019 |
|
rs45430
|
|
|
0.820 |
GeneticVariation |
BEFREE |
A single nucleotide polymorphism (SNP), rs45430, in an intron of the MX2 gene, was previously reported as a novel melanoma susceptibility locus in genome-wide association studies.
|
31660681 |
2019 |
|
rs1805007
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The rs1042522 was also selected as a CM risk factor in multivariate models, suggesting an effect that is independent from and complementary to that of rs1805007.
|
31612033 |
2019 |